W. Va. judge sides with drug distributors in bellwether opioid trial
MedCity News
JULY 7, 2022
From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.
96 
Pharma-biotech dealmaking incentives shift amid a continued drought in financing
Clarivate
OCTOBER 31, 2023
What do the years 2001, 2007, 2014, and 2022 have in common? Investment strategy Industry commentators in the biopharma industry believe the upcoming years are expected to be a period of increased dealmaking activity. In short, the biotech bubble had burst.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Interchangeability of biosimilars in the EU – the industry impact
European Pharmaceutical Review
DECEMBER 19, 2022
Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. Information guide for healthcare professionals, EMA and EU Commission updated 2/10/2019. Directive 2001/83 (as amended). References/Endnotes. Biosimilars in the EU.
PM360 Announces 2023 Trailblazer Award Finalists
PM360
AUGUST 24, 2023
Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcare providers, and happier and healthier people around the world.” Weiss has also made substantial efforts to give back to the community at large.
PM360 Announces 2023 Trailblazer Award Winners
PM360
OCTOBER 5, 2023
Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved into Real Chemistry. Men’s Health: Nuvan Augustin Dassanaike, Senior Vice President Digital and Marketing Strategy & Operations, Accord BioPharma Nephrology/Urology: W. Braun Medical, Inc.
Meet the company on a mission to transform research and advance healthcare
Pharmaceutical Technology
FEBRUARY 20, 2023
This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. Hans Bunschoten: Viroclinics was founded in 2001, spun out of a university setting.
Let's personalize your content